Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas Launches Kiklin Capsules, Copromotes with SKK
June 26, 2012
- ACE Inhibitors Approved for Pediatric Use: MSD, AZ, Shionogi, Kyowa Pharmaceutical
June 26, 2012
- Amlodipine Besylate Approved for Supplemental Indication of Pediatric Hypertension, Generic Versions also Approved
June 26, 2012
- Pfizer Remains Top, Takeda Ranks 12th in World Ranking in FY2011
June 26, 2012
- EvaluatePharma Forecasts Januvia to Become World’s Best-Selling Product in 2018
June 25, 2012
- RaQualia Receives Substance Patent Evaluation in US for 5-HT2B Antagonist
June 25, 2012
- Otsuka, UCB Japan Apply for E Keppra for Pediatric Epilepsy
June 25, 2012
- GSK, DSP Launch Paxil CR Tablets
June 25, 2012
- Nexium Approved for Prevention of GU and DU in Patients Receiving Low-Dose Aspirin: Daiichi Sankyo, AZ
June 25, 2012
- Lyrica Approved for Pain Associated with Fibromyalgia: Pfizer Japan
June 25, 2012
- Two Generic Drug Makers Offer Different Views on Impact of Generic Name-based Prescriptions
June 22, 2012
- Ratio of Generic Name Prescribing Up 30% in 2 Doctor Surveys
June 22, 2012
- Takeda Files MAAs for 2 Fixed-Dose Alogliptin Combination Drugs in Europe
June 21, 2012
- Takeda to Terminate Development of Anti-HGF Antibody; Return Rights to Galaxy of the US
June 21, 2012
- Teijin Pharma to Build New Laboratory to Support Increased Feburic Production and New Drug Development
June 21, 2012
- IBL, Trans Genic to Create Joint Venture for Diagnostic Agent Development and Clinical Tests
June 21, 2012
- Daiichi Sankyo to Market Ranbaxy Products in Venezuela
June 21, 2012
- Kyowa Hakko Kirin Reports Significant Decrease in Off Time with Parkinson’s Disease Drug that is Currently Under Approval Review
June 20, 2012
- RDKK Aims at Sales of 55.5 Billion Yen in 2014 Driven by Personalized Medicine: President Ogasawara
June 20, 2012
- Concrete Price Negotiations to Get Underway by August or September: President Choufuku of Mediceo
June 19, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…